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Abstract
To confirm the diagnostic accuracy of candidate biomarkers in stroke-associ-
ated pneumonia (SAP), we prospectively enrolled ischemic stroke patients with
NIHSS ≥ 10 on admission from March-2016 to August-2017. Blood samples
were collected at baseline, 24 and 48 h after stroke onset. Biomarkers (MR-
proADM, suPAR, SAA) were determined by immunoassays. Regarding
biomarkers, MR-proADM at 24 h (P = 0.04) and both suPAR and SAA at 48 h
(P = 0.036 and P = 0.057) were associated with pneumonia. The combination
of SAA > 25.15 mg/dL and suPAR> 3.14 ng/mL at 48 h had 80% sensitivity
and 95.8% specificity when both biomarkers were above the cut-off. The evalu-
ated biomarkers represent promising tools to be evaluated in future large,
prospective studies on SAP. An accurate SAP diagnosis by thorax CT might
help to reduce variability in such studies.
Introduction
Respiratory tract infections occurring within 7 days of
stroke onset have been incorporated under stroke-associ-
ated pneumonia (SAP) term, after adapted definition
from the Centre for Diseases and Control and Prevention
(CDC)1 by the Pneumonia in Stroke Consensus Group
(PISCES).2 However, one of the main limitations in SAP
research is the lack of a gold-standard test for clinical
diagnosis. Thorax high-resolution computed tomography
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(THRCT) is a useful adjunct to conventional radiography
and an accurate study to identify underlying findings in
stroke patients, which could serve as a guide in SAP diag-
nosis. In fact, we have recently reported that this tool rep-
resents an accurate imaging test for the evaluation of
clinical criteria.3
Stroke alters systemic immunity, predisposing patients
to immunosuppression and infections.4 Therefore, the use
of blood biomarkers associated with the systemic inflam-
matory response and the immune changes would be an
interesting starting point for SAP prediction. Some sepsis
biomarkers, recently identified as promising predictors of
stroke-associated infections,5,6 represents interesting can-
didates for SAP. Soluble urokinase-type plasminogen acti-
vator receptor (suPAR), participates in immunologic
functions.7 Pro-adrenomedullin (MR-proADM), seems to
correlate with the severity of pneumonia.8 And serum
amyloid A protein (SAA) with an important role in
attracting leukocytes and immune cells to the sites of
damage.9 We aimed to confirm the diagnostic accuracy of
mentioned candidate biomarkers related to the features
on THRCT.3
Methods
A cohort of 45 consecutive stroke patients was included
in a monocentric, prospective, observational study from
March/2016-August/2017. The study was approved by our
institutional review committee (ID 0103-M1-14). The
patients eligible for the study were those with ischemic
stroke confirmed by CT or magnetic resonance imaging
(MRI) and NIHSS ≥ 10 on patient admission. Stroke
onset to inclusion was ≤24 h, and informed consent
signed by the patient or a relative was needed at inclu-
sion. Mechanical ventilation pneumonia of intensive care
unit transferred patients and antibiotic therapies within
last 24 h previous to hospital admission were exclusion
criteria. Every patient underwent a comprehensive inter-
view, neurological and general examination on admission
and every day after inclusion until the seventh day after
admission by the same neurologist blinded to the patient
study participation. Dysphagia was evaluated within the
first 24 h with the Acute Stroke Dysphagia Screen test.10
Chest X-ray (CXR) and laboratory test were run fol-
lowing neurologist criteria during admission. A THRCT
with volumetric technique acquisition was performed,
without contrast, between 5th and 7th day of admission
in all included patients, independently of the suspicion of
respiratory infection. CT was performed in a 64 detectors
rows equipment. Dosage Modulation: 120–178 Kv. Colli-
mation: 0.5–1 mm, according the equipment. Reconstruc-
tion interval: 1 mm. PITCH could be between 0.8 and 1.
Acquired data reconstruction was done with soft parts
and high spatial frequency double filter. Every THRCT
was evaluated by two skilled thorax radiologists, and dis-
crepancies reviewed by another expert thorax radiologist,
all blinded to the clinical data. Consensus was reached in
cases with disagreement.
In this study, SAP was diagnosed by treating physician
according to diagnostic categories established by the
PISCES criteria.2 PISCES Probable SAP was defined by
the presence of all CDC criteria1 but in the absence of
diagnostic changes on initial CXR and repeated CXR (or
where CXR not undertaken), and no alternative explana-
tion or diagnosis. Likewise, PISCES definite SAP was
diagnosed when all CDC criteria met including diagnostic
CXR changes on at least one CXR.
Blood samples for biomarkers analysis were obtained at
baseline, 24 and 48 h after stroke onset. Then, samples
were centrifuged at 1500g for 15 min at 4°C and serum
and plasma were frozen at 80°C until biomarker mea-
surement.
We measured a 4-blood biomarkers panel including
SAA, MR-proADM, suPAR and CRP. MR-proADM
(BRAHMS MR-proADM KRYPTORTM-
ThermoFisherScientific, MA) and CRP (CardioPhase HS
CRP, Siemens Healthineers Spain)were measured in
plasma EDTA samples and suPAR (Quantiquine ELISA
kit, R&D Systems, MA) was measured in serum. SAA1
was determined in serum with the Meso Scale Discovery
(MSD) Vascular Injury Panel-I ECL assay, as per manu-
facturer’s instructions (MSD, Gaithersburg, MD). All
biomarkers except MR-proADM were assessed in dupli-
cate and the mean intra-assay coefficient of variation
(CV) was <20%. Inter-assay variation was determined
testing two times in each plate with a commercial internal
control (Human serum type AB, male, from clotted,
Table 1. Baseline characteristics of the stroke patients that were
include in the study and received THRCT.
Variable n = 41 %
Male 21 51.2
Age (years old) (mean  range) 75 [67–82]
NIHSS on admission 20 [15–22]
Time to probable SAP (PISCES) (d) (Mean [range]) 1.5 [1–2]
Time to confirmed SAP on THRCT (d) (Mean [range]) 2 [1.5–3.5]
Smoker 12 29.3
Chronic obstructive pulmonary disease 8 19.5
Dysphagia 31 75.6
Urinary tract infection 5 12.1
Phlebitis 1 2.4
Clinical respiratory infection (PISCES Probable) 8 19.5
Stroke associated pneumonia on THRCT
(Bronchopneumonia)
5 12.2
Stroke associated chest infection on THRCT
(Bronchopneumonia + Bronchitis)
8 19.5
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Sigma-Aldrich), and it was <20%. MR-proADM, as
instructed, was assayed by simple. Intra-assay and inter-
assay CV for this method are <10% and <20%, respec-
tively. Biomarker measurement was performed blinded to
clinical information.
Statistical analyses were conducted with Statistical
Packages for Social Sciences (SPSS), version 22. Inter-
group comparisons were performed using Chi-squared
test for categorical variables and Mann–Whitney U test
for continuous variables. Biomarkers were tested for nor-
mality with the Kolgomorov-Smirnoff test. As biomarkers
were not normally distributed, comparisons on biomarker
levels between groups were performed with non-paramet-
ric tests. Intergroup differences were assessed with Mann–
Whitney or Kruskal–Wallis tests. Where relevant,
biomarkers were dichotomized by the cut-off with the
highest predictive accuracy for infections, which was cal-
culated in receptor operating characteristic (ROC) curves.
Sensitivity and specificity for every biomarker cut-off were
evaluated. A P value <0.05 was considered statistically sig-
nificant. Given the small sample size and the preliminary
nature of the study, P values under 0.1 were considered
as trends.
Results
Of the forty-five included patients, 3 died and one pre-
sented with psychomotor agitation that precluded
Figure 1. Biomarker level according to clinical diagnosis of SAP following PISCES criteria. Boxplots represent median and interquartile range in
both no SAP and probable SAP groups. Just P values <0.1 are represented. CRP, C-reactive protein; SAA, serum amyloid-A protein; MR-proADM,
mid-regional proadrenomedullin; suPAR, soluble urokinase-type plasminogen activator receptor.
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THRCT performance. PISCES probable SAP rate was
17.8% (N = 8). There was no patient with PISCES defi-
nite SAP according to treating physician criteria. More-
over, chest radiography low quality was insufficient to a
correct interpretation of some cases to be considered
definitive SAP. Among those mentioned 8 patients, 5
(62.5%) were identified as bronchopneumonia, 2 (25%)
as infectious bronchitis and 1 showed no pathology on
CT. Baseline data is shown in (Table 1). According to
PISCES criteria, patients with probable SAP trended to
had higher levels MR-proADM at 24 (P = 0.083) and
higher levels of suPAR at 48 h (P = 0.095). There were
no significant differences for CRP and SAA among any
visit (Fig. 1).
However, regarding THRCT findings, MR-proADM at
24 h (P = 0.040) and both suPAR and SAA at 48 h
(P = 0.037 and P = 0.057) were associated with pneumo-
nia. At 24 h, a cut-off of MR-proADM > 1.023 nmol/L
had 80% sensitivity and 72.2% specificity for pneumonia.
At 48 h, both SAA > 25.15 mg/dL (60% sensitivity,
85.7% specificity) and suPAR > 3.14 ng/mL (80% sensi-
tivity, 57.1% specificity) were associated with infections.
The combination of SAA > 25.15 mg/dL and
suPAR > 3.14 ng/mL at 48 h had 80% sensitivity and
95.8% specificity when both biomarkers were above the
cut-off, and 60% sensitivity and 94.1% specificity when
one of them was above the cut-off (Fig. 2).
Discussion
Our results provide various key findings, about the most
common complication after stroke. Employment of
THRCT in SAP, could reduce diagnostic discrepancies in
patients with clinical suspicion and low quality chest
radiography. From the evaluated biomarkers, MR-
proADM seems to be the earliest predictor of SAP, when
respiratory infection is yet not suspected. The combina-
tion of SAA/suPAR improves the predictive value, but at
later time-points.
The poor predictive value of previously SAP studied
biomarkers11 and the limited specificity of validated
pneumonia predictive scores12 induce uncertainty in SAP
prediction and diagnosis. This leads to a late start of the
antibiotic treatment, with the unfortunate consequences
associated, or an overuse of antibiotics in patients without
a clear diagnosis, in order to avoid these fatal outcomes,
increasing antibiotic resistance in cases without real SAP.
Therefore, the identification of an early reliable biomar-
ker, could guide respiratory infection management in
stroke patient.
Figure 2. Biomarker level according to radiological diagnosis of SAP using thoracic HRCT findings. Boxplots represent median and interquartile
range in normal, bronchitis and pneumonia groups. Just P values < 0.1 are represented. CRP, C-reactive protein; SAA, serum amyloid-A protein;
MR-proADM, mid-regional proadrenomedullin; suPAR, soluble urokinase-type plasminogen activator receptor.
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Our previous study showed for the first time THRCT
radiological findings of stroke associated respiratory infec-
tions,3 allowing us to conduct this confirmatory study to
test the diagnostic accuracy of candidate biomarkers
related to both clinical and radiological diagnosis. In our
cohort, regarding clinical criteria, patients with probable
SAP had higher levels of all evaluated biomarkers across
the time-points, but without statistical significance. How-
ever, when SAP was diagnosed according to THRCT find-
ings, we found that MR-proADM at 24 h and both
suPAR and SAA at 48 h were significantly associated with
pneumonia. These results may suggest a correlation
between the acute-phase response and development of an
infection, which would expand biomarkers scope of use
because of their predictive value in SAP patients, con-
firmed by THRCT.
According to our results, it is interesting to highlight
the insufficient association of tested biomarkers with SAP
when they are explored regarding clinical criteria. Such
clinical criteria have shown high sensitivity rates (87.5%)
when respiratory infection suspicion is confirmed with
THTCT.3 However, high false positive rate of clinical cri-
teria leads to discrepancies in biomarkers-SAP relation-
ship that clearly improves when compared with THRCT
findings. In fact, with the use of THRCT we would have
been able to give a diagnosis of definitive SAP instead of
probable SAP in seven out of the eight patients with clini-
cal suspicion. Such results are consistent with low accu-
racy of clinical criteria; showing reliable results due to
THRCT performance in this study.
Finally, for post-stroke infections prediction, to define
biomarker´s cut-points in patients with SAP would help
in preventive strategies, especially in early stages. In our
cohort, the combination of SAA > 25.15 mg/dL and
suPAR > 3.14 ng/mL at 48 h showed 80% sensitivity and
95.8% specificity. Given most SAP cases appears within
first seven days after stroke onset,2 the availability of
described biomarkers, even after 48 h, could help in early
detection of respiratory infection in stroke patients, with
low rates of false negative results.
Therefore, these new cut-offs should now be tested in
larger cohorts, since prospectively validating a cut-off is a
necessary and relevant approach in the biomarkers
research field that we do not usually do systematically.
The main limitation of the study is that our results are
based on a single cohort and our findings need to be vali-
dated in an independent and larger cohort before an
intervention based on these results may be recommended.
In addition, the small sample size and the low rate of
events in both clinical and radiological diagnosis pre-
vented us to perform logistic regression analysis to adjust
by potential confounders, such as stroke severity or dys-
phagia. However, we consider that given laboratory test
are compared for the first time with THRCT findings,
this adds important strength to our study.
In conclusion, among explored biomarkers, MR-
proADM would have an important role in SAP predic-
tion, due to its early elevation in stroke patients suffering
respiratory infections later on. In addition, the combina-
tion of SAA/suPAR improves the predictive value, espe-
cially adding specificity, but at later time-points. Further
prospective studies should be developed to assess the pre-
dictive value of these results. An accurate SAP diagnosis
by thorax CT might help to reduce diagnostic uncertainty
in such studies.
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